Exogenous fetuin-A protects against sepsis-induced myocardial injury by inhibiting oxidative stress and inflammation in mice
dc.contributor.author | Sidheeque Hassan, V. | |
dc.contributor.author | Hanifa, Mohd | |
dc.contributor.author | Navik, Umashanker | |
dc.contributor.author | Bali, Anjana | |
dc.date.accessioned | 2024-01-21T10:55:09Z | |
dc.date.accessioned | 2024-08-14T07:44:23Z | |
dc.date.available | 2024-01-21T10:55:09Z | |
dc.date.available | 2024-08-14T07:44:23Z | |
dc.date.issued | 2023-01-17T00:00:00 | |
dc.description.abstract | Sepsis-induced myocardial injury is a consequence of septicemia and is one of the major causes of death in intensive care units. A serum glycoprotein called fetuin-A is secreted largely by the liver, tongue, placenta, and adipose tissue. Fetuin-A has a variety of biological and pharmacological properties. The anti-inflammatory and antioxidant glycoprotein fetuin-A has shown its efficacy in a number of inflammatory disorders including sepsis. However, its protective role against sepsis-induced myocardial injury remains elusive. The purpose of this work is to explore the role of fetuin-A in mouse models of myocardial injury brought on by cecal ligation and puncture (CLP). CLP significantly induced the myocardial injury assessed in terms of elevated myocardial markers (serum CK-MB, cTnI levels), inflammatory markers (IL-6, TNF-?) in the serum, and oxidative stress markers (increased MDA levels and decreased reduced glutathione) in heart tissue homogenate following 24 h of ligation and puncture. Further, hematoxylin and eosin (H&E) staining showed considerable histological alterations in the myocardial tissue of sepsis-developed mice. Interestingly, fetuin-A pretreatment (50 and 100 mg/kg) for 4 days before the CLP procedure significantly improved the myocardial injury and was evaluated in perspective of a reduction in the CK-MB, cTnI levels, IL-6, and TNF-? in sepsis-developed animals. Fetuin-A pretreatment significantly attenuated the oxidative stress and improved the myocardial morphology in a dose-dependent manner. The present study provides preliminary evidence that fetuin-A exerts protection against sepsis-induced cardiac dysfunction in vivo via suppression of inflammation and oxidative damage. � 2023 Soci�t� Fran�aise de Pharmacologie et de Th�rapeutique. | en_US |
dc.identifier.doi | 10.1111/fcp.12870 | |
dc.identifier.issn | 7673981 | |
dc.identifier.uri | https://kr.cup.edu.in/handle/32116/4356 | |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/fcp.12870 | |
dc.language.iso | en_US | en_US |
dc.publisher | John Wiley and Sons Inc | en_US |
dc.subject | fetuin-A | en_US |
dc.subject | inflammation | en_US |
dc.subject | myocardial injury | en_US |
dc.subject | oxidative stress | en_US |
dc.subject | sepsis | en_US |
dc.subject | TNF-? | en_US |
dc.title | Exogenous fetuin-A protects against sepsis-induced myocardial injury by inhibiting oxidative stress and inflammation in mice | en_US |
dc.title.journal | Fundamental and Clinical Pharmacology | en_US |
dc.type | Article | en_US |
dc.type.accesstype | Closed Access | en_US |